Vascular Manifestations in Antiphospholipid Syndrome (APS): Is APS a Thrombophilia or a Vasculopathy?

about

Vascular Manifestations in Antiphospholipid Syndrome (APS): Is APS a Thrombophilia or a Vasculopathy?

Item

http://www.wikidata.org/entity/Q48035289

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Vascular Manifestations in Ant ...... rombophilia or a Vasculopathy?

@en

Vascular Manifestations in Antiphospholipid Syndrome

@nl

type

Item

label

Vascular Manifestations in Ant ...... rombophilia or a Vasculopathy?

@en

Vascular Manifestations in Antiphospholipid Syndrome

@nl

prefLabel

Vascular Manifestations in Ant ...... rombophilia or a Vasculopathy?

@en

Vascular Manifestations in Antiphospholipid Syndrome

@nl

P1476

Vascular Manifestations in Ant ...... rombophilia or a Vasculopathy?

@en

P2093

Guillaume Canaud

http://www.w3.org/2001/XMLSchema#string

Jessie Risse

http://www.w3.org/2001/XMLSchema#string

Salma Siddique

http://www.w3.org/2001/XMLSchema#string

Stéphane Zuily

http://www.w3.org/2001/XMLSchema#string

P2860

Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity

mTOR signaling in growth control and disease

AKT/PKB signaling: navigating downstream

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides.

Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study.

Sneddon syndrome with or without antiphospholipid antibodies. A comparative study in 46 patients.

A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome.

Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes.

P2888

s11926-017-0687-z

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11926-017-0687-Z

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28871481

http://www.w3.org/2001/XMLSchema#string

P921

thrombophilia